Hyperlipidemia as a risk factor of renal allograft function impairment

被引:34
作者
Carvalho, MFC [1 ]
Soares, V [1 ]
机构
[1] UNESP, Botucatu Med Sch, Dept Internal Med, Div Nephrol, Botucatu, SP, Brazil
关键词
dyslipidemia; hypercholesterolemia; hypertriglyceridemia; kidney transplantation; renal allograft;
D O I
10.1034/j.1399-0012.2001.150108.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
In this study, the graft outcome in renal allograft recipients with [high cholesterol group (HCG), n = 30] or without [normal cholesterol group (NCG), n = 42] hypercholesterolemia and with [high triglyceride group (HTG), n = 33] or without [normal triglyceride group (NTG), n = 36] hypertriglyceridemia were prospectively compared. At 6 months post-transplantation, no significant difference was observed between the groups (NTG compared with HTG, and NCG compared with HCG) regarding age, presence of arterial hypertension, kind of donor (living related or cadaveric), immunosuppressive therapy, number of rejection episodes per patient, frequency of patients with acute cellular rejection, prevalence of patients with diabetes mellitus or proteinuria > 3 g/24 h, and mean serum creatinine. The probability of doubling serum creatinine during follow-up was statistically different between NTG and HTG (12 months: NTG = 0.03, HTG = 0.15; 36 months: NTG = 0.08, HTG = 0.33; 60 months: NTG = 0.08, HTG = 0.48; and 120 months: NTG = 0.18, HTG = 0.48), but not between NCG and HCG (12 months: NCG = 0.05, HCG = 0.13; 36 months: NCG = 0.13, HCG = 0.24; 60 months: NCG = 0.19, HCG = 0.31; 84 months: NCG = 0.27, HCG = 0.31). There was no significant difference in actuarial graft survival between HCG and NCG or between NTG and HTG. Hypertriglyceridemia, but not hypercholesterolemia, was associated with loss of graft function.
引用
收藏
页码:48 / 52
页数:5
相关论文
共 9 条
  • [1] NONIMMUNOLOGICAL CAUSES OF LATE RENAL GRAFT LOSS - DISCUSSION
    BIA, MJ
    HARRINGTON, JT
    BERNSTEIN, P
    BASADONNA, G
    HAYSLETT, J
    DOOLAN, P
    FINKELSTEIN, F
    KASHGARIAN, M
    JUERGENSON, P
    ELLISON, D
    [J]. KIDNEY INTERNATIONAL, 1995, 47 (05) : 1470 - 1480
  • [2] CATTRAN DC, 1979, ANN INTERN MED, V91, P554, DOI 10.7326/0003-4819-91-4-554
  • [3] THE INFLUENCE OF PRETRANSPLANT LIPOPROTEIN ABNORMALITIES ON THE EARLY RESULTS OF RENAL-TRANSPLANTATION
    DIMENY, E
    TUFVESON, G
    LITHELL, H
    LARSSON, E
    SIEGBAHN, A
    FELLSTROM, B
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1993, 23 (09) : 572 - 579
  • [4] DIMENY E, 1993, CLIN TRANSPLANT, V7, P482
  • [5] HYPERLIPIDEMIA IN STABLE RENAL-TRANSPLANT RECIPIENTS
    DIVAKAR, D
    BAILEY, RR
    FRAMPTON, CM
    GEORGE, PM
    WALMSLEY, TA
    MURPHY, J
    [J]. NEPHRON, 1991, 59 (03): : 423 - 428
  • [6] GUIJARRO C, 1995, KIDNEY INT, V48, pS56
  • [7] RISK-FACTORS PREDICTING CHRONIC REJECTION OF RENAL-ALLOGRAFTS
    ISONIEMI, H
    NURMINEN, H
    TIKKANEN, MJ
    VONWILLEBRAND, E
    KROGERUS, L
    AHONEN, J
    EKLUND, B
    HOCKERSTEDT, K
    SALMELA, K
    HAYRY, P
    [J]. TRANSPLANTATION, 1994, 57 (01) : 68 - 72
  • [8] Swan SK, 1997, CONTRIB NEPHROL, V120, P62
  • [9] LIPID ABNORMALITIES IN CYCLOSPORINE-PREDNISONE-TREATED RENAL-TRANSPLANT RECIPIENTS
    VATHSALA, A
    WEINBERG, RB
    SCHOENBERG, L
    GREVEL, J
    GOLDSTEIN, RA
    VANBUREN, CT
    LEWIS, RM
    KAHAN, BD
    [J]. TRANSPLANTATION, 1989, 48 (01) : 37 - 43